At a glance
- Originator GlaxoSmithKline
- Class Antidepressants; Anxiolytics
- Mechanism of Action Serotonin 2C receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 19 Nov 2001 Discontinued-I for Anxiety disorders in United Kingdom (Unknown route)
- 19 Nov 2001 Discontinued-I for Depression in United Kingdom (Unknown route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline